Ann: Medibio Quarterly Update and Cashflow Report, page-4

Looking for this trend to continue for the business to ensure a half decent runaway for 2019.



Worth remembering the R&D rebate for 2019 in terms of cash flow later in the year.

Do agree with many statements from @Monster_User, looking for clarity from the business in regards to the formal 510K submission. I've raised with the business previously the need to have a go to market plan in regions where the business does have regulatory approval. I believe they are working on this.

It will be good to see the rights issue formally close next Friday, so the business can get on with, well 'business'... Start delivering and seeing some level of price appreciation that won't get arb'ed into.